FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

Published Date: 27 May 2025

A study led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal tumor with multilayered ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Understudied mental health challenges among caregivers of cancer patients: A call for targeted support

2.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

3.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

4.

The hidden costs of cancer for young survivors are derailing their financial futures

5.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot